Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Ohlbe – France, 2020-02-05 10:13 (236 d 08:16 ago) – Posting: # 21147
Views: 1,036

Dear Qualityassurance,

» Can anyone suggest me :confused::confused: if it is required to include these medications in concomitant medication experiment if the route of administration is other than oral (e.g. IV, topical, eye drops) during clinical phase?

I would say it depends on the bioavailability of these products when administered by these routes. For IV, no discussion (at least, if there is an active substance - don't bother about saline or glucose). But for a topical administration the answer is likely that there is no point.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,084 posts in 4,398 threads, 1,468 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Monday 19:30 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5